XERIS BIOPHARMA HOLDINGS, INC. Investing Cash Flow
XERIS BIOPHARMA HOLDINGS, INC. (XERS) reported Investing Cash Flow of -$534.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivities · last filed 2026-08-06
- XERIS BIOPHARMA HOLDINGS, INC. net cash provided by (used in) investing activities for the quarter ending 2026-06-30 was -$209.00K.
- XERIS BIOPHARMA HOLDINGS, INC. net cash provided by (used in) investing activities for the quarter ending 2026-03-31 was -$325.00K.
- XERIS BIOPHARMA HOLDINGS, INC. net cash provided by (used in) investing activities for the quarter ending 2025-12-31 was -$333.00K, a 103.32% decline year-over-year.
- XERIS BIOPHARMA HOLDINGS, INC. net cash provided by (used in) investing activities for the quarter ending 2025-09-30 was -$71.00K, a 100.72% decline year-over-year.
- XERIS BIOPHARMA HOLDINGS, INC. net cash provided by (used in) investing activities for fiscal 2025 was -$696.00K, a 114.25% decline from fiscal 2024.
- XERIS BIOPHARMA HOLDINGS, INC. net cash provided by (used in) investing activities for fiscal 2024 was $4.88M.
- XERIS BIOPHARMA HOLDINGS, INC. net cash provided by (used in) investing activities for fiscal 2023 was -$6.00M, a 117.42% decline from fiscal 2022.
- XERIS BIOPHARMA HOLDINGS, INC. net cash provided by (used in) investing activities for fiscal 2022 was $34.46M, a 64.82% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Investing Activities 3 month | Net Cash Provided by (Used in) Investing Activities 6 month | Net Cash Provided by (Used in) Investing Activities 9 month | Net Cash Provided by (Used in) Investing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$209.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$534.00K 10-Q · filed 2026-08-06 | -$867.00K derived: sum of 3 quarters · filed 2026-08-06 | -$938.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$325.00K 10-Q · filed 2026-05-07 | -$658.00K derived: sum of 2 quarters · filed 2026-05-07 | -$729.00K derived: sum of 3 quarters · filed 2026-05-07 | -$1.01M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$333.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | -$404.00K derived: sum of 2 quarters · filed 2026-03-02 | -$683.00K derived: sum of 3 quarters · filed 2026-08-06 | -$696.00K 10-K · filed 2026-03-02 |
| 2025-09-30 | -$71.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$350.00K derived: sum of 2 quarters · filed 2026-08-06 | -$363.00K 10-Q · filed 2025-11-06 | $9.65M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$279.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$292.00K 10-Q · filed 2026-08-06 | $9.72M derived: sum of 3 quarters · filed 2026-08-06 | $19.64M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$13.00K 10-Q · filed 2026-05-07 | $10.00M derived: sum of 2 quarters · filed 2026-05-07 | $19.92M derived: sum of 3 quarters · filed 2026-05-07 | $24.52M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $10.02M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $19.93M derived: sum of 2 quarters · filed 2026-03-02 | $24.53M derived: sum of 3 quarters · filed 2026-03-02 | $4.88M 10-K · filed 2026-03-02 |
| 2024-09-30 | $9.91M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $14.52M derived: sum of 2 quarters · filed 2025-11-06 | -$5.13M 10-Q · filed 2025-11-06 | $9.73M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-06-30 | $4.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$15.05M 10-Q · filed 2025-08-07 | -$179.00K derived: sum of 3 quarters · filed 2026-03-02 | $14.48M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-03-31 | -$19.65M 10-Q · filed 2025-05-08 | -$4.78M derived: sum of 2 quarters · filed 2026-03-02 | $9.87M derived: sum of 3 quarters · filed 2026-03-02 | $18.32M derived: sum of 4 quarters · filed 2026-03-02 |
| 2023-12-31 | $14.87M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $29.52M derived: sum of 2 quarters · filed 2026-03-02 | $37.98M derived: sum of 3 quarters · filed 2026-03-02 | -$6.00M 10-K · filed 2026-03-02 |
| 2023-09-30 | $14.65M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-08 | $23.11M derived: sum of 2 quarters · filed 2024-11-08 | -$20.87M 10-Q · filed 2024-11-08 | -$11.70M derived: sum of 4 quarters · filed 2025-03-06 |
| 2023-06-30 | $8.45M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$35.53M 10-Q · filed 2024-08-08 | -$26.36M derived: sum of 3 quarters · filed 2025-03-06 | -$19.65M derived: sum of 4 quarters · filed 2025-03-06 |
| 2023-03-31 | -$43.98M 10-Q · filed 2024-05-09 | -$34.81M derived: sum of 2 quarters · filed 2025-03-06 | -$28.10M derived: sum of 3 quarters · filed 2025-03-06 | -$16.23M derived: sum of 4 quarters · filed 2025-03-06 |
| 2022-12-31 | $9.17M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $15.88M derived: sum of 2 quarters · filed 2025-03-06 | $27.75M derived: sum of 3 quarters · filed 2025-03-06 | $34.46M 10-K · filed 2025-03-06 |
| 2022-09-30 | $6.71M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $18.58M derived: sum of 2 quarters · filed 2023-11-09 | $25.29M 10-Q · filed 2023-11-09 | $61.90M derived: sum of 4 quarters · filed 2024-03-06 |
| 2022-06-30 | $11.87M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $18.58M 10-Q · filed 2023-08-08 | $55.19M derived: sum of 3 quarters · filed 2024-03-06 | $73.69M derived: sum of 4 quarters · filed 2024-03-06 |
| 2022-03-31 | $6.72M 10-Q · filed 2023-05-09 | $43.32M derived: sum of 2 quarters · filed 2024-03-06 | $61.82M derived: sum of 3 quarters · filed 2024-03-06 | $78.38M derived: sum of 4 quarters · filed 2024-03-06 |
| 2021-12-31 | $36.60M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-06 | $55.11M derived: sum of 2 quarters · filed 2024-03-06 | $71.66M derived: sum of 3 quarters · filed 2024-03-06 | $97.96M 10-K · filed 2024-03-06 |
| 2021-09-30 | $18.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $35.06M derived: sum of 2 quarters · filed 2022-11-09 | $61.36M 10-Q · filed 2022-11-09 | $68.61M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | $16.56M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | $42.86M 10-Q · filed 2022-08-10 | $50.11M derived: sum of 3 quarters · filed 2022-08-10 | |
| 2021-03-31 | $26.30M 10-Q · filed 2022-05-11 | $33.55M derived: sum of 2 quarters · filed 2022-05-11 | ||
| 2020-12-31 | $7.25M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-11 | -$27.41M 10-K · filed 2022-03-11 | ||
| 2020-09-30 | -$34.65M 10-Q · filed 2021-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |